The elevated preoperative fasting blood glucose predicts a poor prognosis in patients with esophageal squamous cell carcinoma: The Fujian prospective investigation of cancer (FIESTA) study

Diabetes as a latent risk factor for cancer has been extensively investigated, while its postoperative prognosis for esophageal cancer is rarely reported. We therefore sought to assess whether the elevated fasting blood glucose before surgery was associated with poor survival in esophageal cancer pa...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-10, Vol.7 (40), p.65247-65256
Main Authors: Hu, Dan, Peng, Feng, Lin, Xiandong, Chen, Gang, Liang, Binying, Li, Chao, Zhang, Hejun, Liao, Xuehong, Lin, Jinxiu, Zheng, Xiongwei, Niu, Wenquan
Format: Article
Language:English
Subjects:
Adult
Aged
Blood Glucose
Carcinoma, Squamous Cell - blood
Carcinoma, Squamous Cell - mortality
Cohort Studies
Diabetes Complications - mortality
Diabetes Mellitus
Esophageal Neoplasms - blood
Esophageal Neoplasms - mortality
Esophageal Squamous Cell Carcinoma
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Prognosis
Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetes as a latent risk factor for cancer has been extensively investigated, while its postoperative prognosis for esophageal cancer is rarely reported. We therefore sought to assess whether the elevated fasting blood glucose before surgery was associated with poor survival in esophageal cancer patients by eliciting a subset of data from the ongoing Fujian prospective investigation of cancer (FIESTA) study. Over 15-year follow-up, 2535 patients receiving three-field lymphadenectomy were assessable. Only patients with esophageal squamous cell carcinoma (ESCC) (n=2396) were analyzed due to the lower prevalence of the other histological types. In ESCC patients, the follow-up duration ranged from 0.5 to 180 months (median 38.2 months). The median survival time (MST) was remarkably shorter in males than in females (80.7 vs. 180+ months, Log-rank test: P
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.11247